Arch Biopartners Inc (ARCH.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 09/30
(Values in thousands)
| 09-2025 | 09-2024 | 09-2023 | 09-2022 | 09-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2 | 3 | 831 | 506 | 448 |
| Receivables | 78 | 899 | 297 | 87 | 2,201 |
| TOTAL | $105 | $936 | $1,171 | $622 | $2,668 |
| Non-Current Assets | |||||
| TOTAL | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $105 | $936 | $1,171 | $622 | $2,668 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 2,495 | 2,770 | 4,312 | 2,100 | 1,802 |
| Accounts payable and accrued liabilities | 1,042 | 2,352 | 393 | 489 | 962 |
| Accrued Expenses | 0 | 43 | 173 | 190 | 425 |
| TOTAL | $3,986 | $5,283 | $5,977 | $2,779 | $3,189 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | 704 | 2,313 | 3,362 |
| Deferred Revenues | 0 | 118 | 1,099 | N/A | N/A |
| TOTAL | $0 | $0 | $704 | $2,313 | $3,362 |
| Total Liabilities | $3,986 | $5,283 | $6,681 | $5,092 | $6,551 |
| Shareholders' Equity | |||||
| Common Shares | 20,347 | 17,418 | 15,883 | 15,553 | 14,758 |
| Retained earnings | -33,524 | -31,971 | -28,051 | -24,724 | -23,316 |
| Other shareholders' equity | 2,695 | 2,695 | 0 | 0 | 0 |
| TOTAL | $-3,882 | $-4,348 | $-5,510 | $-4,471 | $-3,882 |
| Total Liabilities And Equity | $105 | $936 | $1,171 | $622 | $2,668 |